Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 14/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801672 | 1.00 | MC4R (1.00) | MC4RKCNH2NISCH | |
| SCHEMBL4368953 | 0.94 | MC4R (0.89) | MC4RKCNH2 | |
| Hydrochloric Acid SCHEMBL4902641 | 0.93 | MC4R (0.87) | MC4RKCNH2 | |
| SCHEMBL4823402 | 0.88 | MC4R (0.79) | MC4RKCNH2NISCH | |
| SCHEMBL4071377 | 0.88 | KCNH2 (1.00) | MC4RKCNH2 | |
| SCHEMBL4822664 | 0.86 | MC4R (0.76) | MC4RKCNH2NISCH | |
| SCHEMBL4822799 | 0.86 | MC4R (0.75) | MC4RKCNH2 | |
| SCHEMBL4823900 | 0.86 | MC4R (0.75) | MC4RKCNH2NISCH | |
| SCHEMBL4819955 | 0.85 | MC4R (0.74) | MC4RKCNH2NISCH | |
| SCHEMBL4011110 | 0.84 | MC4R (0.73) | MC4RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12156867-B2 | Melanocortin agents for use in the therapeutic treatment of melanoma, tumors of the gastrointestinal tract, and thyroid carcinoma | UNIVERSITA' DI PISA (IT) | 2024-12-03 | — | — | US | disclosed |
| EP-3806851-B1 | MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA | UNIV PISA (IT) | 2022-07-20 | — | — | EP | disclosed |
| EP-3806851-A1 | MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA | Università di Pisa (IT) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019243974-A1 | MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA | UNIVERSITA' DI PISA (IT) | 2019-12-26 | — | — | WO | disclosed |
| EP-2101806-B1 | TREATMENT OF PARKINSON'S DISEASE OR PARKINSONIAN DISORDERS USING AGENTS THAT DECREASE THE ACTIVITY OF THE MELANOCORTIN 4 RECEPTOR | NEURONOVA AB (SE) | 2013-05-01 | — | — | EP | disclosed |
| US-20100129319-A1 | TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM USING AGENTS THAT DECREASE THE ACTIVITY OF THE MELANOCORTIN 4 RECEPTOR | NEWRON SWEDEN AB (SE) | 2010-05-27 | — | — | US | disclosed |
| EP-2101806-A2 | TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM USING AGENTS THAT DECREASE THE ACTIVITY OF THE MELANOCORTIN 4 RECEPTOR | NeuroNova AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008071438-A2 | TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM USING AGENTS THAT DECREASE THE ACTIVITY OF THE MELANOCORTIN 4 RECEPTOR | NEURONOVA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070021433-A1 | Pharmacological chaperones for treating obesity | UNIVERSITE DE MONTREAL (CA) | 2007-01-25 | — | — | US | disclosed |
| EP-1644337-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Gene Logic, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005121100-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | GENE LOGIC INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129319-A1 | TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM USING AGENTS THAT DECREASE THE ACTIVITY OF THE MELANOCORTIN 4 RECEPTOR | MC4R, MC3R, MC5R | MC4R 1/4885KCNH2 4218/4885NISCH 470/4885 |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | MC4R 1/4885KCNH2 3035/4885NISCH 1934/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | MC4R 1/4885KCNH2 3648/4885NISCH 2500/4885 |
| US-12156867-B2 | Melanocortin agents for use in the therapeutic treatment of melanoma, tumors of the gastrointestinal tract, and thyroid carcinoma | MC4R, MC3R, MC1R | MC4R 1/4885KCNH2 4291/4885NISCH 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.